Lilly and Boehringer roll toward EU approval with diabetes combo

Eli Lilly ($LLY) and Boehringer Ingelheim secured a recommendation from European regulators for their combination diabetes treatment, making for a likely continental approval in the coming months. The drug is a fixed-dose combination of empagliflozin, an SGLT-2 inhibitor that forces excess blood sugars out through the urine, and metformin, a long-generic treatment designed to block glucose production in the liver. The pair plans to market the combination as Synjardy, expecting to pick up FDA approval later this year. Empagliflozin won approval last year and is marketed as Jardiance. More

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.